Korean South West Oncology Group
4
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
25.0%
1 terminated/withdrawn out of 4 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (4)
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
Role: lead
A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy
Role: lead
A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment
Role: lead
Docetaxel and Oxaliplatin Combination With Locally Advanced or Metastatic Biliary Tract Cancer
Role: lead
All 4 trials loaded